One-year overall survival was 83% for related donor hematopoietic cell transplantation recipients compared to 62% for unrelated donor recipients among patients with severe aplastic anemia.
Cohort (n=1,718)
Yes
What is the burden of late effects and survival in patients undergoing HCT for severe aplastic anemia?
HCT survivors with severe aplastic anemia generally have good survival, though unrelated donor HCT is associated with lower survival and a higher burden of late effects compared to related donor HCT.
Absolute Event Rate: 83% vs 62%
Objective: With improvements in hematopoietic cell transplantation (HCT) for severe aplastic anemia (SAA), there is a growing population of SAA survivors of HCT.However, there is a paucity of information regarding late effects in SAA HCT survivors.We analyzed the burden of malignant and non-malignant late effects in HCT survivors with acquired SAA.Methods: A descriptive analysis of 1,718 patients post-HCT for acquired SAA between 1995-2006 reported to the CIBMTR was conducted.Cumulative incidences (CI) of selected late effects are reported for among ''condition-free'' (i.e.survivors without a previous diagnosis of the specified late effect) HCT survivors with SAA.Results: One-year overall survival for the recipients of related donor HCT was 83% (80-85) and 62% (58-66) for the recipients of unrelated donor HCT.Of the HCT recipients, 1176 (68.5%) patients with a median age at HCT of 20 years (\1-65) utilized a related donor and 542 (31.5%) patients with a median age at HCT of 20 years (\1-67) utilized an unrelated donor.The median interval from diagnosis to transplant was 3 months (\1-348) for related donor HCT and 14 months (1-318) for unrelated donor HCT.Radiation (of any type) was utilized in 6% and 78% of related and unrelated donor HCT cases; respectively.Cy-TBI (68%) was a commonly utilized conditioning regimen for unrelated donor HCT.The median follow-up is 70 months (1-160) and 67 months (3-182) for related and unrelated donor HCT; respectively.The 2-year CI of chronic GVHD was 20% (18-22) and 37% (32-41) in related and unrelated donor HCT; respectively.Table 1 demonstrates that among 1-year condition-free survivors, the CI of late effects is greater among unrelated donor HCT survivors and continues to increase.Conclusion: These findings suggest that HCT survviors with SAA are a robust and healthy group in general.However, subgroups of patients undergoing HCT for SAA are at-risk for late effects and must be educated about and should be monitored for late effects.Subgroups of survivors may be at-risk group for a greater burden of spe-cific late effects.Ongoing analyses in our cohort will explore selected risk-factors for late effects after HCT for SAA.
Chow et al. (Tue,) conducted a cohort in Acquired severe aplastic anemia (n=1,718). Related donor hematopoietic cell transplantation vs. Unrelated donor hematopoietic cell transplantation was evaluated on 1-year overall survival. One-year overall survival was 83% for related donor hematopoietic cell transplantation recipients compared to 62% for unrelated donor recipients among patients with severe aplastic anemia.